Table 4.
Relationships between Tregs and survival of patients with HCC.
| Tregs markers | Class | Tregs conditions | OS | DFS | References |
|---|---|---|---|---|---|
| CD4+Foxp3+ | HCC | High TIT and high intratumoral IL-17 (+) T-cells | (−) | (−) | 97 |
| High TIT and high peritumoral IL-17 (+) T-cells | (−) | (−) | |||
| CD4+Foxp3+ | HCC | High TIT and low intratumoral CTLs | (−) | (−) | 113, 121 |
| Low TIT and low peritumoral CTLs | (+) | (+) | |||
| Low TIT and high peritumoral CTLs | (−) | (−) | |||
| High CTLs | (+) | No | |||
| CD4+Foxp3+ | HCC | High TIT | (−) | (−) | 77, 88, 91, 92, 113, 114 |
| CD4+Foxp3+ | Early stage HCC | High PBT and TIT | (−) | No | 55 |
| Balance of CD8+ T-cells and TIT | No | No | |||
| CD4+Foxp3+ | HCC | High ratio of TIT/CD8+ T-cells | (−) | (−) | 123 |
| CD4+CD25+Foxp3+ | HCC | High TIT | No | (−) | 124 |
Tregs: regulatory T-cells; HCC: hepatocellular carcinoma; OS: overall survival; DFS: disease-free survival; CD: cluster of differentiation; Foxp3: forkhead box protein 3; TIT: tumor infiltrating Tregs; IL-17: interleukin-17; CTL: cytotoxic lymphocyte; PBT: peripheral blood Tregs; (+): better prognosis; (−): worse prognosis; No: no correlation.